NEW YORK, December 11, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on QDEL, PETS, VRX, and ARDM which is a click away at http://www.wallstequities.com/registration. Market Realist reported that the Healthcare sector had a strong performance in November 2017. The Health Care Select Sector SPDR ETF (XLV), which tracks the performance of the Healthcare sector, rose 2.9% in November 2017. On a year-to-date basis, it has returned 22.4% as of December 01st, 2017. Pre-market today, WallStEquities.com shifts focus on the performance of Quidel Corp. (NASDAQ: QDEL), PetMed Express Inc. (NASDAQ: PETS), Valeant Pharmaceuticals International Inc. (NYSE: VRX), and Aradigm Corp. (NASDAQ: ARDM). Wall St. Equities has a wide array of free research reports which include today's stock picks, register now to access them at:
California headquartered Quidel Corp.'s shares recorded a trading volume of 364,017 shares last Friday. The stock finished the trading session 1.79% higher at $40.40. The Company's shares have gained 7.13% in the last one month, 11.29% over the previous three months, and 88.61% since the start of this year. The stock is trading above its 200-day moving average by 29.21%. Furthermore, shares of Quidel, which develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, POC women's and general health, and gastrointestinal diseases, have a Relative Strength Index (RSI) of 54.66.
On November 27th, 2017, Quidel acknowledged Beckman Coulter's ("Beckman") plans to pursue commercial litigation to allow it to sell BNP directly to customers, contrary to its agreement with Quidel for the development, manufacture, and supply of a B-type Naturietic Peptide assay for the diagnosis of cardiac disease (the "Supply Agreement"). Quidel views Beckman's claims as meritless, and plans to vigorously defend the validity of the Supply Agreement. Follow the link below to your free research report on QDEL at:
On Friday, Florida headquartered PetMed Express Inc.'s stock ended the session 0.51% lower at $42.87. A total volume of 487,751 shares was traded. The Company's shares have gained 16.15% in the last one month, 15.40% over the previous three months, and 85.83% on an YTD basis. The stock is trading 14.75% above its 50-day moving average and 25.28% above its 200-day moving average. Moreover, shares of PetMed Express, which operates as a pet pharmacy in the US, have an RSI of 68.92. The free technical report on PETS can be accessed at:
Valeant Pharmaceuticals International
Canada headquartered Valeant Pharmaceuticals International Inc.'s stock ended the day 11.74% higher at $19.70. A total volume of 44.77 million shares was traded, which was above their three months average volume of 13.24 million shares. The Company's shares have surged 32.39% in the last month, 38.83% over the previous three months, and 35.67% on an YTD basis. The stock is trading 38.28% and 45.69% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Valeant Pharma have an RSI of 76.35.
On December 07th, 2017, Valeant Pharma announced that Scott A. Hirsch, Senior Vice President and Chief Business Strategy Officer, and Arthur J. Shannon, Senior Vice President and head of Investor Relations and Communications, are scheduled to participate at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14th, 2017, at 2:00 p.m. EST in New York. Sign up for free on Wall St. Equities and claim the latest report on VRX at:http://www.wallstequities.com/registration/?symbol=VRX
Shares in California headquartered Aradigm Corp. recorded a trading volume of 92,925 shares. The stock ended Friday's session 3.61% higher at $4.33. The Company's shares have gained 23.74% in the last month, 220.81% over the previous three months, and 170.69% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.80% and 105.11%, respectively. Furthermore, shares of Aradigm, which focuses on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases, have an RSI of 57.90.
On December 01st, 2017, Aradigm announced that a meeting of the Antimicrobial Drugs Advisory Committee of the US FDA has been scheduled for January 11th, 2018, to review the Company's NDA for Linhaliq™ for the treatment of non-cystic fibrosis bronchiectasis patients with chronic lung infections with Pseudomonas aeruginosa. The Company submitted the NDA in July 2017, following which the FDA set a PDUFA goal date of January 26th, 2018, for the completion of its review. See the free research coverage on ARDM at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities